⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1687174 | 0.78 | GRIA1 (0.31) | — | |
| SCHEMBL9769783 | 0.73 | ALDH1A1 (0.30) | — | |
| SCHEMBL9854500 | 0.66 | OPRD1 (0.38) | — | |
| SCHEMBL3953839 | 0.63 | — | — | |
| SCHEMBL8412790 | 0.63 | — | — | |
| SCHEMBL7135166 | 0.63 | — | — | |
| SCHEMBL9351591 | 0.63 | — | — | |
| SCHEMBL8189282 | 0.62 | CYP3A4 (0.32) | — | |
| SCHEMBL18274686 | 0.60 | — | — | |
| SCHEMBL3959327 | 0.60 | GRIA1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105745-A1 | Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2010-04-29 | — | — | US | disclosed |
| CN-101460491-A | Anilino-pyrimidine phenyl and benzothiophene analogs | WYETH CORP (US) | 2009-06-17 | — | — | CN | disclosed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1845094-A1 | METHOD OF TUMOR SUPPRESSION AND EVALUATION OF ANTICANCER AGENT BASED ON GSK3 BETA INHIBITORY EFFECT | National University Corporation Kanazawa University (JP) | 2007-10-17 | — | — | EP | disclosed |
| CN-101039919-A | N-benzenesulfonyl substituted anilino-pyrimidine analogs | WYETH CORP (US) | 2007-09-19 | — | — | CN | disclosed |
| CN-1891220-A | Use of 2-amino-3-alkylpyrimidinone derivatives for producing medicaments | SANOFI SYNTHELABO (FR) | 2007-01-10 | — | — | CN | disclosed |
| CN-1891220-A | Use of 2-amino-3-alkylpyrimidinone derivatives for producing medicaments | SANOFI SYNTHELABO (FR) | 2007-01-10 | — | — | CN | disclosed |
| CN-1247567-C | 2-amino-3-alkylpyrimidinone derivatives as GSK3 beta inhibitors | SANOFI AVENTIS (FR) | 2006-03-29 | — | — | CN | disclosed |
| CN-1247567-C | 2-amino-3-alkylpyrimidinone derivatives as GSK3 beta inhibitors | SANOFI AVENTIS (FR) | 2006-03-29 | — | — | CN | disclosed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | disclosed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | disclosed |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | SANOFI (FR) | 2003-10-02 | — | — | US | disclosed |
| CN-1419552-A | 2-amino-3-alkylpyrimidinone derivatives as GSK3 beta inhibitors | SANOFI SYNTHELABO (FR) | 2003-05-21 | — | — | CN | disclosed |
| CN-1419552-A | 2-amino-3-alkylpyrimidinone derivatives as GSK3 beta inhibitors | SANOFI SYNTHELABO (FR) | 2003-05-21 | — | — | CN | disclosed |
| EP-1136482-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors | SANOFI-SYNTHELABO (FR) | 2001-09-26 | — | — | EP | disclosed |